

9 August 2022

Results of General Meeting

Creso Pharma Limited (ASX:CPH) ('Creso Pharma' or 'the Company') held a General Meeting of Members by virtual meeting facility today.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the General Meeting is set out in the Annexure which accompanies this release.

Ends

Authority and Contact Details

This announcement has been authorised for release by Winton Willesee, Joint Company Secretary.

For further information, please contact:

Investor Enquiries

Creso Pharma Limited E: info@cresopharma.com P: +61 (0) 497 571 532

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Disclosure of Proxy Votes

Creso Pharma Limited

General Meeting Tuesday, 09 August 2022



GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes			Poll Results			
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Approval to Issue Options to Lenders	Р	201,997,600	196,791,846 97.42%	2,939,931 1.46%	910,936	2,265,823 1.12%	199,057,669 98.54%	2,939,931 1.46%	910,936
2 Approval to Issue Placement Options	Р	169,873,860	164,317,053 96.73%	3,286,984 1.93%	952,588	2,269,823 1.34%	219,056,279 98.52%	3,286,984 1.48%	952,588
3 Ratification of Prior Issue of Consideration Shares	Р	201,856,916	196,132,699 97.16%	3,352,194 1.66%	1,051,620	2,372,023 1.18%	250,974,125 98.68%	3,352,194 1.32%	1,051,620
4 Approval to Issue Performance Shares	Р	202,233,269	195,550,314 96.70%	4,396,932 2.17%	675,267	2,286,023 1.13%	250,305,740 98.27%	4,396,932 1.73%	675,267
5 Creation of a New Class of Securities – Performance Shares	Р	202,013,857	195,544,712 96.80%	4,175,522 2.07%	894,279	2,293,623 1.14%	250,307,738 98.36%	4,175,522 1.64%	894,279
6 Ratification of Prior Issue of Options to Brett Ayers	Р	201,850,243	195,490,435 96.85%	4,072,685 2.02%	1,058,293	2,287,123 1.13%	250,246,961 98.40%	4,072,685 1.60%	1,058,293
7 Ratification of Prior Issue of Options to Kevin Tansey	Р	201,847,593	195,487,635 96.85%	4,075,485 2.02%	1,060,943	2,284,473 1.13%	250,241,511 98.40%	4,075,485 1.60%	1,060,943

			Proxy Votes				Poll Results		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Ratification of Prior Issue of Options to Odeon Nominees	Р	201,675,366	195,495,169 96.94%	3,889,724 1.93%	1,233,170	2,290,473 1.14%	250,255,045 98.47%	3,889,724 1.53%	1,233,170
9 Ratification of Prior Issue of Shares to Noble House Consulting Ltd	Р	196,553,940	189,575,905 96.45%	4,690,912 2.39%	6,354,596	2,287,123 1.16%	244,332,431 98.12%	4,690,912 1.88%	6,354,596
10 Approval of Issue of Securities – Section 611 (Item 7) of the Corporations Act	Р	201,911,238	195,616,393 96.88%	3,699,254 1.83%	997,298	2,595,591 1.29%	250,681,387 98.55%	3,699,254 1.45%	997,298